Baxter International Inc.
) declared the commercial launch of HEMOPATCH Sealing Hemostat,
following CE mark approval in Europe. The development of this new
collagen-based hemostatic device showcases the strong expertise
of the company in collagen, internal coagulation processes and
PEG (polyethylene glycol) technology platforms.
BAXTER INTL (BAX): Free Stock Analysis Report
BIO-RAD LABS -A (BIO): Free Stock Analysis
BOSTON SCIENTIF (BSX): Free Stock Analysis
INSYS THERAP (INSY): Free Stock Analysis
To read this article on Zacks.com click here.
The HEMOPATCH is an important addition to Baxter's BioSurgery
product portfolio, which consists of a range of biological and
synthetic products and delivery devices used for hemostasis,
tissue sealing, adhesion reduction, hard tissue regeneration, as
well as soft tissue repair and microsurgery products.
Hemostasis is a physiological process which stops bleeding
resulting from a cut or injury. Bleeding in surgical procedures
is a major problem encountered by all surgeons. Complications
from excessive bleeding may include blood loss, tissue damage,
infection and excessive scarring. If uncontrolled, it can even
turn out to be life-threatening.
Baxter's HEMOPATCH will provide a unique solution to this
problem. It is a resorbable hemostatic device effectively
designed to stop bleeding in surgical situations where other
conventional methods often fail.
The thin, soft and flexible collagen pad allows surgeons to
attain rapid hemostasis, as it firmly adheres to the bleeding
tissue surface. Further, the specially-formulated porous collagen
matrix, covered on one side with a thin protein bonding layer,
known as NHS-PEG, helps to seal off the bleeding surface,
initiating the body's own clotting process.
The new surgical tool promises to be a boon for surgeons. It is
quick and effective, requires zero preparation time, and can be
applied to varied surgical settings. Preclinical testing has also
guaranteed the product's hemostatic performance,
biocompatibility, and safety profile.
Baxter plans to launch the new bio surgical product in other
countries as well.
Recently it launched HyQvia, a replacement therapy for adults
with primary and secondary immunodeficiencies, in Germany.
Additional product launches in the European markets are also on
Baxter currently carries a Zacks Rank #3 (Hold). Other stocks
that are worth a look include
Bio-Rad Laboratories, Inc.
INSYS Therapeutics, Inc.
), each carrying a Zacks Rank #1 (Strong Buy) and
Boston Scientific Corp.
) carrying a Zacks Rank #2 (Buy).